NASDAQ:SYRE Spyre Therapeutics Q3 2025 Earnings Report $87.25 +0.20 (+0.23%) As of 04:00 PM Eastern ProfileEarnings HistoryForecast Spyre Therapeutics EPS ResultsActual EPS-$0.15Consensus EPS -$0.68Beat/MissBeat by +$0.53One Year Ago EPSN/ASpyre Therapeutics Revenue ResultsActual RevenueN/AExpected Revenue$0.10 millionBeat/MissN/AYoY Revenue GrowthN/ASpyre Therapeutics Announcement DetailsQuarterQ3 2025Date11/4/2025TimeBefore Market OpensConference Call DateTuesday, November 4, 2025Conference Call Time7:00AM ETUpcoming EarningsSpyre Therapeutics' Q3 2026 earnings is estimated for Tuesday, November 3, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 6, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsEarnings Release(8-K)Quarterly Report(10-Q) Spyre Therapeutics Earnings HeadlinesSpyre Therapeutics to Participate in Upcoming September Investor ConferencesSeptember 3 at 4:05 PM | globenewswire.comSpyre (SYRE) Fell 13% on Its Weakest Program. Its Best One Just WorkedSeptember 1 at 3:23 AM | finance.yahoo.comTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result.September 3 at 1:00 AM | Porter & Company (Ad)Analysts Offer Insights on Healthcare Companies: Revolution Medicines (RVMD) and Spyre Therapeutics (SYRE)August 30, 2026 | theglobeandmail.comAnalysts Offer Insights on Healthcare Companies: Solventum Corporation (SOLV), Argenx Se (ARGX) and Spyre Therapeutics (SYRE)August 28, 2026 | theglobeandmail.comSpyre Therapeutics (NASDAQ:SYRE) Shares Gap Down After Analyst DowngradeAugust 28, 2026 | americanbankingnews.comSee More Spyre Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Spyre Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Spyre Therapeutics and other key companies, straight to your email. Email Address About Spyre TherapeuticsSpyre Therapeutics (NASDAQ:SYRE) is a clinical-stage biotechnology company focused on the discovery and development of novel immunotherapies for cancer. The company leverages proprietary protein engineering and biologics design platforms to create targeted molecules intended to enhance anti-tumor immune responses and inhibit tumor growth. Its preclinical pipeline comprises multiple candidate therapies for solid tumor and hematologic oncology indications. Established by a team with deep expertise in protein design, immunology and translational research, Spyre Therapeutics collaborates with leading academic institutions and research organizations to accelerate its discovery efforts. The company utilizes advanced screening technologies and a modular engineering approach to optimize therapeutic candidates, streamline preclinical development and position its programs for clinical readiness. Based in the United States, Spyre Therapeutics operates a modern research and development facility that supports both in-house projects and external partnerships. Led by a management team experienced in biopharmaceutical innovation and development, the company is working to advance its lead programs into human trials and aims to bring new treatment options to patients with high-need cancers.View Spyre Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles AeroVironment’s $465 Million Army Laser Win Expands Its Counter-Drone OpportunityThe Path to $230 Billion: Broadcom Outlines the Next Phase of Its AI Growth StoryPalo Alto Networks Is Expensive—But Its Growth Is AcceleratingMongoDB’s Spending Fears Collide With a Much Stronger Growth StoryGitLab’s Earnings Beat Just Gave Software Bulls a New SaaSpocalypse TestWith the RSI at a Record Low, Is It Time to Go Bargain Hunting on Burlington?Enova’s Earnings Surge Meets a Valuation Test Upcoming Earnings Oracle (9/8/2026)Adobe (9/10/2026)FedEx (9/17/2026)Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/8/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
